Related Experiment Video
Updated: Feb 9, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Lactulose as a novel template for anticancer drug development targeting galectins
Chandan Kishor1, Renee L Ross1, Helen Blanchard1
1Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia.
Lactulose, a sugar, shows potential as a novel scaffold for developing galectin inhibitors. This research reveals its binding affinity and structural interactions, paving the way for new cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Galectins are carbohydrate-binding proteins implicated in cancer progression, including metastasis and immune evasion.
- Targeting galectin-carbohydrate interactions requires specific inhibitors, but suitable scaffolds are limited.
Purpose of the Study:
- To investigate lactulose as a novel inhibitor scaffold for galectins.
- To elucidate the molecular interactions between lactulose and galectin-1/galectin-3.
- To propose lactulose derivatives as potential anti-cancer agents.
Main Methods:
- Thermodynamic evaluation to assess binding affinity.
- X-ray crystallography to determine complex structures.
- Molecular modeling to design novel derivatives.
Main Results:
- Lactulose demonstrated binding affinity for the galectin-1 and galectin-3 carbohydrate recognition domains.
- Crystal structures revealed the precise molecular basis of lactulose-galectin interactions.
- Molecular modeling identified potential lactulose derivatives as potent anti-cancer agents.
Conclusions:
- Lactulose serves as a promising scaffold for designing specific galectin inhibitors.
- Understanding these interactions is crucial for developing targeted cancer therapies.
- Novel lactulose derivatives warrant further investigation as anti-cancer drugs.
Related Concept Videos
DNA as a Genetic Template
DNA as a Genetic Template
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
In Vitro Drug Release Testing: Overview, Development and Validation
Sustainable Development
Development of the Lymphatic System
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...

